Results 21 to 30 of about 23,180 (193)

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. [PDF]

open access: yes, 2011
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human ...
Aderie, Endashaw Mengistu   +6 more
core   +2 more sources

Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. [PDF]

open access: yes, 2016
Aspergillus spp. are a group of filamentous molds that were first described due to a perceived similarity to an aspergillum, or liturgical device used to sprinkle holy water, when viewed under a microscope.
Stewart, Ethan R, Thompson, George R
core   +3 more sources

Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris [PDF]

open access: yes, 2017
The emerging multidrug-resistant yeast pathogen Candida auris has attracted considerable attention as a source of healthcare–associated infections. We report that this highly virulent yeast has the capacity to form antifungal resistant biofilms sensitive
Borman, Andrew   +6 more
core   +4 more sources

Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis

open access: yesMedical Mycology Case Reports, 2017
A 54-year-old woman with acute myeloid leukemia (AML) achieved complete remission by induction chemotherapy, but developed zygomycosis after consolidation therapy.
Testuro Ochi   +8 more
doaj   +1 more source

Potency and stability of liposomal Amphotericin B formulated for topical management of Aspergillus spp. infections in burn patients

open access: yesBurns Open, 2020
Background: Systemic fungal infections are an important mortality factor when considering severely burned patients. Preventive topical pharmacotherapeutic management of deep fungal infections remains of secondary concern when initially treating a burn ...
Alexis Laurent   +8 more
doaj   +1 more source

Low castes have poor access to visceral leishmaniasis treatment in Bihar, India [PDF]

open access: yes, 2012
Objectives  Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases in the country. A large proportion of the poor rural communities where VL is endemic are marginalized by their socio-economic status, intrinsically ...
Alvar   +22 more
core   +2 more sources

Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2019
INTRODUCTION: Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.
Tália Santana Machado de Assis   +4 more
doaj   +1 more source

HIV-associated disseminated histoplasmosis successfully treated with isavuconazole consolidation therapy

open access: yesMedical Mycology Case Reports, 2020
A 30-year-old man with advanced HIV and disseminated histoplasmosis deteriorated after stepping down from intravenous liposomal amphotericin B to itraconazole.Therapeutic levels of itraconazole and posaconazole were not achieved, therefore liposomal ...
Andrea Mazzella   +5 more
doaj   +1 more source

Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report [PDF]

open access: yes, 2001
Background Mucormycosis (or zygomycosis) is the term for infection caused by fungi of the order Mucorales. Mucoraceae may produce severe disease in susceptible individuals, notably patients with diabetes and leukemia.
MG Rinaldi   +14 more
core   +2 more sources

Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2019
In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate.
Benivaldo Ramos Ferreira Terceiro   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy